You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Aveo reeling after FDA’s rejection of kidney cancer drug

It took Aveo Pharmaceuticals Inc. seven years to develop a much anticipated kidney cancer drug. Federal regulators needed only about four hours to crush the company’s hopes.

The Cambridge biotech’s executives were brimming with confidence when they arrived for a Food and Drug Administration advisory committee meeting May 2 in Silver Spring, Md. The panel was expected to recommend that the drug — known as tivozanib — be approved for sale. Instead, Aveo’s leaders endured a gut-wrenching morning, starting with the first speaker.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week